Ipilimumab biosimilar - Eden Biologics
Alternative Names: EB 1003; JHL-1152Latest Information Update: 28 Jun 2024
At a glance
- Originator JHL Biotech
- Developer Eden Biologics
- Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Malignant melanoma
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Malignant-melanoma(Late-stage disease) in Taiwan (Parenteral)
- 26 Aug 2021 Ipilimumab biosimilar - Eden Biologics is available for licensing in World as of 26 Aug 2021. https://www.edenbiologics.com/pipeline-3/
- 12 May 2020 Preclinical trials in Malignant melanoma (Late-stage disease) in Taiwan (Parenteral) (JHL Biotech pipeline, May 2020)